Using Real World Evidence to Complement Traditional Healthcare Metrics
For years pharmaceutical and biotechnology firms have determined the effectiveness of therapeutic drug treatments using randomized clinical trials (RCTs). These trials have been the go to source for determining the safety, efficacy and performance of drugs. However, the emerging healthcare technologies have opened a whole new world of data known as Real World Evidence (RWE). Real World Evidence can best be described as data collected under normal day to day circumstances found outside of a normal RCT (www.clinicalinformaticsnews.com).
RWE closes the knowledge gap between the RCT, which focus on a small highly selected set of individuals, and real life experiences, which encase a broader reflection of an entire population’s experience in the real world, in real time. Through the analysis and data assessment of an individual’s illness, deep insights reveal there are numerous factors at play and the impact of these factors can vary from one day to the next i.e. comorbidity, psychological impact, symptom management, daily interactions, stigma, Quality of Life (QoL) etc. Understanding how these factors play a role in an individual’s life sheds light on the necessary steps to improving overall health. Using RWE, the entire ecosystem from patients to health care providers can use real world health outcomes to better assess the value of drug treatments and related services (Congizant, 2020 Insights).
The Self Care Catalysts’ (SCC) Health Storylines™ self-care management platform provides a solution for patients to log, track and monitor their daily experiences while the Patient Storylines™ analytics platform is the real world, real-time unique intelligence solution that aggregates and anonymizes the patient data sets to reveal insights.
Currently underway at SCC is the Spondy Project, which focuses on individuals living with Ankylosing Spondylitis (AS). AS is a form of chronic inflammation of the spine sacroiliac joints (located at the base of the lower back) that affects between 0.2% to 0.5% of all North Americans. The objective of the Spondy project is to gain deeper insights into the real-life daily experiences and interactions of individuals living with AS. The specific data collated is based on the use of tools such as the Medication Tracker, Daily Moods, Symptom Tracker, Fatigue Tracker and Treatment Reflections.
Preliminary results analyzed through the Patient Storylines™ analytics platform show a strong correlation between the clinically-validated Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire and daily reports of the overall impact of patients’ symptoms, collected through the Health Storylines™ app. The continual assessment of AS patients’ real life, real time behaviour is a novel use of technology that will drive the final results of the AS study, helping to identify key drivers that can improve overall health care and management of AS.
Real World Evidence can shed light on specific disease therapies uncovering patient insights that are not commonly associated with a disease. Research from real world patient data is an increasingly important asset that can revolutionize better care delivery and long term health outcomes.